Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Rehab program shows promise for scleroderma Patients' daily life

NCT ID NCT00318188

Symptom relief Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a personalized rehabilitation program could improve quality of life for people with systemic sclerosis, a disease that causes skin and joint stiffness. 220 adults with the condition were randomly assigned to either the rehab program or usual care. The program focused on exercises and activities to reduce disability and improve daily function.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
personalized standardized rehabilitation program
What this could lead to
If successful, this could offer a non-drug way to improve daily function and quality of life for people with systemic sclerosis.
What could go wrong
This is a completed trial, but rehabilitation effects can vary widely. The program may not work for everyone, and results depend on patient adherence.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

220 people

The number who actually took part.

Started

Sep 2005

Finished

Jan 2014

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men or women aged from 18 years or more, with diagnostic of SSc considering the ACR and/or Leroy and Medsger's criteria. * HAQ greater than or equal to 0.5 * A perception of limitation of mouth opening and/or at least one limitation in range of motion due to illness * Good understanding of the French language Exclusion Criteria : * Associated chronic handicap diseases (stroke, multiple sclerosis, amyotrophic lateral sclerosis, Parkinson's disease, amputated ....) * Any underlying disease that may be incompatible with the management, discovery at the inclusion visit * Cognitive problems making it impossible to assess the primary outcome measure * Patients with a standardized rehabilitation program within 6 months prior to inclusion * Impairment of comprehension or expression of the French language * Patients participating in another clinical trial or participated in another clinical trial in the previous 3 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Systemic scleroderma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diffuse scleroderma systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Systemic scleroderma

Contacts and locations

Locations

  • Reeducation and readaptation Department

    Paris, 75679, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.